Beta

Avalon globocare corp.ALBT.US Overview

US StockReal Estate
(No presentation for ALBT)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ALBT AI Insights

ALBT Overall Performance

ALBT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALBT Recent Performance

1.95%

Avalon globocare corp.

0.39%

Avg of Sector

-0.49%

S&P500

ALBT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ALBT's Trend

ALBT Key Information

ALBT Valuation Metrics

ALBT Profile

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Price of ALBT

ALBT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALBT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
8.64
PB Ratio
7.51
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
25.70%
Net Margin
-1355.20%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
3.32%
3-Year Profit Growth
18.11%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
8.64
PB Ratio
7.51
Price-to-FCF
-
Gross Margin
25.70%
Net Margin
-1355.20%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
3.32%
3-Year Profit Growth
18.11%

  • When is ALBT's latest earnings report released?

    The most recent financial report for Avalon globocare corp. (ALBT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALBT's short-term business performance and financial health. For the latest updates on ALBT's earnings releases, visit this page regularly.

  • What is the operating profit of ALBT?

    According to the latest financial report, Avalon globocare corp. (ALBT) reported an Operating Profit of -1.82M with an Operating Margin of 173.32% this period, representing a decline of 38.93% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ALBT's revenue growth?

    In the latest financial report, Avalon globocare corp. (ALBT) announced revenue of -1.05M, with a Year-Over-Year growth rate of -403.76%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ALBT have?

    At the end of the period, Avalon globocare corp. (ALBT) held Total Cash and Cash Equivalents of 109.09K, accounting for 0 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ALBT go with three margins increasing?

    In the latest report, Avalon globocare corp. (ALBT) achieved the “three margins increasing” benchmark, with a gross margin of 27.1%%, operating margin of 173.32%%, and net margin of 196.7%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ALBT's profit trajectory and future growth potential.

  • Is ALBT's EPS continuing to grow?

    According to the past four quarterly reports, Avalon globocare corp. (ALBT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.46. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALBT?

    Avalon globocare corp. (ALBT)'s Free Cash Flow (FCF) for the period is -563.63K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 47.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ALBT?

    The latest valuation data shows Avalon globocare corp. (ALBT) has a Price-To-Earnings (PE) ratio of -0.25 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.